Last Price
41.26
Today's Change
-2.45 (5.60%)
Day's Change
41.23 - 45.00
Trading Volume
868,184
Market Cap
2 Billion
Shares Outstanding
52 Million
Avg Volume
569,935
Avg Price (50 Days)
42.09
Avg Price (200 Days)
32.76
PE Ratio
-46.89
EPS
-0.88
Earnings Announcement
05-Nov-2024
Previous Close
43.71
Open
44.68
Day's Range
41.23 - 45.0
Year Range
5.65 - 65.6
Trading Volume
868,184
1 Day Change
-5.61%
5 Day Change
-12.25%
1 Month Change
16.92%
3 Month Change
-6.57%
6 Month Change
1.60%
Ytd Change
274.41%
1 Year Change
287.05%
3 Year Change
39.49%
5 Year Change
64.06%
10 Year Change
64.06%
Max Change
64.06%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.